Picture this: In a nation celebrated for its slender figures and disciplined lifestyles, an insidious obsession with thinness is driving people to risk their health by misusing powerful diet drugs. This alarming trend in South Korea, where obesity rates are among the lowest globally, reveals a darker side to beauty ideals fueled by social media and unchecked access to medications. But here's where it gets controversial – are we sacrificing well-being for a fleeting image, and who decides what's 'too thin' anyway? Let's dive in and unpack this complex issue step by step, shedding light on the facts and sparking some deeper reflections.
As of December 8, 2025, South Korea is witnessing a surge in demand for weight-loss medications, despite being one of the leanest countries in the OECD (Organisation for Economic Co-operation and Development). This boom is driven by intense societal pressures around body image and the ease of obtaining these drugs, raising red flags among health experts. At the same time, a fresh wave of oral GLP-1 medications – these are glucagon-like peptide-1 agonists, which work by mimicking a hormone that regulates appetite and blood sugar – is poised to hit the market soon, potentially accelerating the trend.
For instance, Eli Lilly's oral GLP-1 drug, orforglipron, could become available in Korea as early as next year, pending approval from the U.S. Food and Drug Administration, according to recent media reports. Novo Nordisk's 25-milligram oral semaglutide is also in the review pipeline. Locally, Korean pharmaceutical giant Hanmi Pharmaceutical is gearing up to launch its GLP-1 treatment, efpeglenatide, in the latter half of next year, broadening the arsenal for managing obesity and diabetes.
To put this into a global context, obesity is escalating as a worldwide health crisis. Just last week, the World Health Organization (WHO) released groundbreaking guidelines advocating GLP-1 therapies for treating obesity not as a simple condition, but as a chronic, recurring illness that demands ongoing care. This marks a significant shift in how we approach weight management.
And this is the part most people miss – even though South Korea boasts one of the lowest obesity rates in the OECD when measured by WHO standards (a mere 5.7 percent of the population), local health officials are sounding the alarm about a creeping problem. The country employs a stricter benchmark for obesity, defining it as a body mass index (BMI) of 25 or higher – that's lower than the global norm, which starts at 30. Under this local criterion, the percentage of adults classified as obese has been climbing steadily, reflecting a hidden epidemic of weight-related issues.
But here's a twist that fuels the fire: Despite being designed for medical use, these anti-obesity drugs have skyrocketed in popularity for purely cosmetic reasons, leading to rampant misuse. Take Novo Nordisk's Wegovy, which arrived in Korea in October last year – it has already shown troubling signs of being abused.
Data from the Health Insurance Review & Assessment Service paints a stark picture: As of August, the drug was illicitly prescribed to 69 children under 12 and 194 pregnant women, groups explicitly banned from using it due to potential risks to developing bodies and unborn babies. Moreover, prescriptions were doled out by specialists far removed from obesity treatment – think psychiatrists, urologists, ophthalmologists, and even dentists – who may lack the expertise for such therapies.
Authorities also flagged 111 instances of unlawful advertising in the first half of this year, often enticing people to get the drug without the oversight of a qualified doctor. Under Korea's BMI 25 threshold, 41.4 percent of men are deemed obese, almost twice the 23 percent of women. Yet, women make up a whopping 71.5 percent of prescriptions for Wegovy and the similar injectable Saxenda between 2020 and June 2025. While official numbers on non-medical use are scarce, plenty of anecdotal stories suggest it's widespread, prompting experts to worry about a slippery slope toward dependency.
Now, let's zero in on the elephant in the room: Social media's role in amplifying these pressures. In this digital era, South Korea's fixation on thinness has reached fever pitch, amplified by online platforms.
In July, the government-backed Korea Health Promotion Institute released a public alert decrying the spread of warped body ideals online. They spotlighted the 'bony arm' trend, where forearms are so slender that bone contours are visible, hailed as the ultimate desirable look. The institute points out that idolizing these ultra-thin celebrity physiques has fueled a 39 percent spike in eating disorder cases from 2020 to 2023. 'Phenomena like the 'bony arm' represent a clear danger to public health, particularly for teenagers and females,' warned institute head Kim Heon-joo.
A joint study from professors at Changwon National University and Soongsil University delved deeper, finding that young women bombarded with pro-anorexia content online follow a troubling path: starting with a yearning for slimness, progressing to achieving it, and then sustaining it through digital cheerleading from online groups. This echoes international findings, such as Facebook's own research leaked to the Wall Street Journal in 2021, which revealed that Instagram exacerbates body image woes among adolescent girls, with platform-specific harms including heightened anxiety and distorted self-perception.
Experts argue that these virtual worlds, brimming with diet vlogs, transformation reels, and 'bone skinny' how-tos, are warping what society deems an 'ideal' body and nudging even non-obese individuals toward prescription meds. But is this just harmless aspiration, or a toxic cycle that demands intervention? And this is the part most people miss – by glorifying extremes, are platforms inadvertently promoting disordered eating as a lifestyle choice?
Amid all this, health officials urge caution, even as obesity creeps upward under domestic metrics. South Korea's 2024 obesity rate stands at 34.4 percent using the BMI 25 benchmark, a jump from 26.3 percent in 2015. Over half of men in their 30s and 40s now qualify as obese. Yet, public awareness lags: A survey by the Korean Society for the Study of Obesity showed only 38 percent of non-healthcare respondents see obesity as a disease, versus 90 percent of doctors. Many cling to the notion that willpower alone can conquer excess weight, underestimating its biological roots.
Authorities emphasize that while more medically overweight patients warrant expanded access to therapies, using GLP-1 drugs casually for vanity purposes invites needless dangers. In October, the Ministry of Health and Welfare unveiled plans to classify Wegovy, Saxenda, and similar drugs as high-risk for misuse or addiction.
'Individuals with a normal BMI who pop these pills just to shed pounds for appearance's sake expose themselves to serious side effects, like anemia, hair thinning, and muscle wasting,' cautioned Kang Jae-hun, a family medicine professor at Kangbuk Samsung Hospital.
So, where do we draw the line? Is the pursuit of thinness empowering or enslaving? Should governments step in to regulate social media's influence on body ideals, or is personal choice the ultimate arbiter? Do you agree that obesity deserves treatment as a disease, or is it still a matter of self-control? And here's a controversial angle: Could these drugs democratize weight loss, leveling the playing field for those struggling – or are they just enabling a dangerous obsession? We'd love to hear your take – share your opinions in the comments below and let's discuss!
